Emerging treatments

Factor IX gene therapy: etranacogene dezaparvovec

Etranacogene dezaparvovec is a gene therapy product, approved in the US and Europe for the treatment of adults with congenital hemophilia B who currently use factor IX prophylaxis therapy or who have current or historical life-threatening bleeding or repeated, serious spontaneous bleeding episodes. It is not approved for use in patients with a history of factor IX inhibitors or patients under 18 years of age. It is administered as a single intravenous infusion. Etranacogene dezaparvovec uses an adeno-associated virus (AAV)-5 vector that delivers a codon-optimized factor IX Padua variant transgene with a liver-specific promoter sequence.[70]​ In a phase 3 trial, a single infusion of etranacogene dezaparvovec was given to 54 men with severe or moderately severe hemophilia B following at least 6 months of factor IX prophylaxis. Follow-up for 18 months post treatment was completed by 53 participants. The study showed that etranacogene dezaparvovec is superior to factor IX prophylaxis for annualized bleeding rate. Increased factor IX activity was seen from 3 weeks after treatment and sustained over 18 months. Most participants (52 out of 54) stopped taking prophylactic factor IX; of those who continued, one received only a partial dose of etranacogene dezaparvovec and the other had the highest AAV-5 neutralizing antibody titer in the study. Adverse reactions included liver enzyme elevations, headache, mild infusion-related reactions, and flu-like symptoms.[104][105] Etranacogene dezaparvovec may have the potential to reduce the burden of care and improve quality of life for patients with severe or moderately severe hemophilia. However, it is a high-cost treatment and there is a lack of long-term data. Research is ongoing to monitor the longer term safety and efficacy.

Factor IX gene therapy: investigational therapies

Several other factor IX gene therapy products are undergoing clinical investigation. Long-term data on adeno-associated virus (AAV)-8 factor IX gene therapy showed sustained factor IX level, at a mean of approximately 5 IU/dL for up to 10 years.[106] High-level factor IX expression (mean 33.7 IU/dL for 28-78 weeks) was reported following infusion of fidanacogene elaparvovec a single-stranded AAV vector comprising a bioengineered capsid (SPARK 100), liver-specific promoter, and factor IX Padua (factor IX-R338L, a gain of function factor IX variant) transgene (Spark).[107] Results at 5-year follow-up showed that fidanacogene elaparvovec was generally well tolerated. Mean factor IX activity remained in the mild hemophilia severity range and no patients resumed factor IX prophylaxis. A phase 3 study is underway.[108][109]​ The Food and Drug Administration (FDA) is currently reviewing an application for approval of fidanacogene elaparvovec for the treatment of hemophilia B.

Factor VIII gene therapy: valoctocogene roxaparvovec

Factor VIII gene therapy is challenging because of the large factor VIII complementary DNA (cDNA) size (7 kb), which limits insertion into AAV vectors. Modifications, such as factor VIII B-domain deletion and codon optimization, have resulted in a gene construct that is able to fit into an AAV vector.[110][111]​​​ The Biomarin AAV 5-factor VIII (also known as valoctocogene roxaparvovec) phase 3 study showed factor VIII levels at a mean of 77 IU/dL at 35 weeks.[112] An updated long-term follow-up at 3 years and 5 years showed clinically relevant benefit with substantial reduction in annualized bleeding rate.[113][114]​​​ There is, however, a concern about the long-term sustainability/durability of factor VIII gene expression. The median factor VIII activity in the high vector dose group (6 × 10¹³ vg/kg) dropped gradually from 60 IU/dL at year 1, to 20 IU/dL at year 3, and 8.2 IU/dL at year 5; while in the mid vector dose group (4 × 10¹³ vg/kg), the median factor VIII level dropped from 23 IU/dL at year 1, to 13 IU/dL at year 2, and 4.8 IU/dL at year 4.[113][114][115]​​​ The interim data from Biomarin's phase 3 trial in 132 patients receiving a high vector dose (6 × 10¹³ vg/kg) showed a mean factor VIII level of 42.9 IU/dL (median 23.9 IU/dL) at year 1, dropping to mean 24.4 IU/dL (median 14.4 IU/dL) at year 2.[116] Trial participants will continue to be closely monitored for longer term safety and efficacy.[117]​ Valoctocogene roxaparvovec is approved in the US and Europe for the treatment of adults with severe hemophilia A without antibodies to AAV5 (identified by an approved screening test for anti-AAV5 antibodies).

Factor VIII gene therapy: investigational therapies

​A phase 1-2 trial of the AAV vector (SPK-8011) factor VIII gene therapy showed sustained factor VIII expression in 12 participants followed up for more than 2 years, permitting discontinuation of prophylaxis and a reduction in bleeding episodes with no major safety concerns.[118]​ A phase 3 trial is planned. Another phase 3 trial (NCT4370054) on recombinant AAV 2/6-factor VIII gene therapy is recruiting.[119]

Half-life extension technologies

Several technologies to extend factor half-life are the subject of ongoing research: fusion of the factor VIIa molecule to the C terminus peptide of human chorionic gonadotropin (factor VIIa-CTP); linking albumin to the factor VIIa molecule (factor VIIa-FP); a novel fusion protein, factor VIIIFc-VWF-XTEN, consisting of the factor VIII binding D'D3 domains of von Willebrand factor fused to a single-chain recombinant factor VIIIFc.[120][121]​​[122]​ Clinical trials of extended half-life products in children and previously untransfused patients are in progress or have been published.[123][124][125][126]

Fitusiran

Fitusiran (also known as ALN-AT3), an investigational silencing RNA (siRNA), targets antithrombin (III) mRNA in the liver, with the goal of reducing circulating levels of antithrombin to a degree that enhances thrombin generation in an acceptably safe manner.[127] A phase 3 clinical trial of fitusiran showed significant reduction in bleeding rates (overall, joint, spontaneous; all by approximately 90%, compared with on-demand replacement factor therapy), with meaningful improvement in health-related quality of life.[128] 

Concizumab

Concizumab is a humanized monoclonal antibody against the K2 domain of tissue factor pathway inhibitor (TFPI), the primary inhibitor of the initiation of coagulation. Administration has been shown to improve thrombin generation in healthy volunteers and hemophilia A and hemophilia B patients with or without inhibitors.[129] Phase 3 clinical trials are ongoing.[130][131][132][133][134][135]

Marstacimab

Marstacimab is a human monoclonal antibody against the K2 domain of TFPI.[136] A phase 3 crossover study of marstacimab for hemophilia A or B with or without inhibitors is ongoing.[137][138]

von Willebrand factor-containing products

There is some evidence to suggest that von Willebrand factor (VWF)/factor VIII complex may reduce inhibitor levels in patients with high-risk factors for poor immune tolerance induction (ITI) outcome or who have previously failed ITI.[47][139][140]

Use of this content is subject to our disclaimer